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Allen Buchanan’s latest book, Beyond Humanity, is a
refreshingly subtle, biologically informed defense of
biomedical enhancement. Buchanan doesn’t take a pro-
enhancement position so much as (in his words) an ‘anti-
anti-enhancement’ position (13). This distinguishes him
from conservatives like Leon Kass and Michael Sandel,
who decry the use of medicine to improve our existing
capacities, but who tepidly embrace it to treat disease.
But it also sets him apart from ethicists like Julian
Savulescu, who recently suggested that we have a moral
obligation to enhance ourselves and our children under
certain conditions.
One of the common assumptions of the anti-
enhancement view that Buchanan challenges is that there
is a timeless ‘essence’ or ‘end’ of medicine, and that any
deviation from this end by patients and physicians is
wrong (27). Buchanan is skeptical of essentialist talk in
medicine, and suggests instead that medicine is valuable
to the extent that it can make our lives go better. In this
sense, Buchanan argues, medicine is a lot like numeracy,
literacy, and scientific knowledge: it can be used to make
us better off or worse off, depending on the purposes to
which we put it. Buchanan’s response to the problem of
risk is not to condemn science for giving us the power to
create nuclear weapons or biotechnology for allowing us
to create more aggressive soldiers. It is rather to face up
to the fact that new ideas bring new responsibilities, and,
if used appropriately, have the power to increase human
welfare dramatically.
An often neglected aspect of enhancement, Buchanan
thinks, is that people with improved capacities can benefit
other people as well as themselves. Since free markets
facilitate the division of labor and diffusion of ideas, a
world with more people who have the creative capacity of
Albert Einstein or Steve Jobs is a world in which many
people can be made better off without worsening the lot
of others. Moreover, Buchanan argues, some enhance-
ments have network effects, so that as more people
acquire them, more people benefit (48). An example is a
well-functioning immune system. People with poorly
functioning (but not necessarily diseased) immune
systems are not only more likely to be infected with
pathogenic microbes, they are also more likely to spread
them to others. By contrast, when more people have
immunity to a particular pathogen (whether the immu-
nity is produced through vaccination, genetic mutation,
or gene therapy) everyone is better off. This is because
the probability of contracting a transmissible disease is
often related to the number of people infected. When this
is true, those with poorly functioning immune systems
benefit from other people’s immuno-enhancements
nearly as much as they themselves do, and the benefits to
the unenhanced increase exponentially with the number
and quality of others people’s enhancements.
Of course, not all enhancements are like this. While
many biomedical interventions can benefit both the
enhanced and the unenhanced, others present unforesee-
able risks to those who undertake them, and to those who
decline but who have to suffer the social costs of other
people’s choices. For example, if some parents genetically
enhance their male children to produce higher testos-
terone than average (with the hope, perhaps, that more
assertive sons will be more successful), a predictable side
effect is that in the aggregate we will have a more aggres-
sive population, and possibly a higher rate of violence –
costs that are borne both by those who choose to enhance
their children, and those who forebear. Such choices are
familiar to economists, and they could become common
in the absence of proper social and legal constraints.
A more serious problem, perhaps, is that even
relatively small physical and cognitive enhancements
could exacerbate existing inequalities to the point at
which unenhanced people cannot compete with enhanced
people for access to social goods and political power. One
need only consider that small differences in qualities like
height, intelligence, and humor can produce big gains in
wealth, opportunities, and access to mates. Sexual selec-
tion can produce significant differences in these qualities
within a few generations, and rapid advances in biomedi-
cal technology could turn out to be like sexual selection
on steroids.
The worry about stratification is a common one, and
Buchanan has at least a couple of replies. One reply is
that biomedical technologies like cognitive enhancement
drugs would benefit the less well endowed much more
than they benefit the better endowed: the relative gains of
people who have a poor memory, for example, will be
larger than those whose memory is already adequate to
lead a reasonably good life. And when these drugs go off
patent, they would be cheap and accessible, thus poten-
tially reducing rather than increasing the gap between
people’s natural endowments. While this is no doubt true,
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it is not fully convincing, especially since rapid advance-
ments in biotechnology might allow the wealthy to gain
large advantages quickly. Thus, even with the eventual
diffusion of drugs to the poor, if biotechnology advances
quickly enough, and if the initial starting point is unequal
enough, the gap between the enhanced and unenhanced
could widen, and disparities in power or well-being may
increase accordingly. Buchanan is well aware of this,
and he spends a significant part of his book addressing
precisely this problem.
In the final chapter, Buchanan outlines an ambitious
plan for reducing global inequalities in access to biomedi-
cal enhancements. Buchanan’s stated goal is to design
political mechanisms that would reduce unjust inequa-
lities ‘without an unacceptable decrease in incentives
for innovation’ (266). The most obvious question here is
what makes an inequality in access to biomedical tech-
nology unjust. Is it simply the size of inequality? Or is
it instead the instrumental effects of inequality – for
example, the extent to which unequal access to enhance-
ments might produce unequal access to economic oppor-
tunities and political power? Buchanan seems to support
the second view: there is nothing intrinsically wrong
with inequality in the distribution of goods, provided it
results from some people improving their own well-being
without undermining other people’s ability to improve
theirs.
In the end, Buchanan argues that the best way to
reduce unjust inequalities in access to biomedical
enhancements is to create a Global Institute for Justice in
Innovation. The GIJI would receive its power from
member states (much like the World Bank and World
Health Organization) and would be tasked with two
functions: incentivizing firms to produce biomedical
innovations for people who normally wouldn’t have
enough money to create a viable market for such pro-
ducts; and pressuring firms to temporarily suspend some
of their monopoly power over innovations that contrib-
ute to extreme inequalities. Although Buchanan’s pro-
posal strikes me as quixotic – especially because it would
disproportionately affect a small handful of firms in a
few powerful countries – it is a thought-provoking and
carefully crafted plan that merits serious study.
Beyond Humanity is a breath of fresh air, and a
welcome antidote to the pessimistic pill that many oppo-
nents of enhancement continue to prescribe. In place of
the misty metaphors and specious arguments that have
pervaded the enhancement debate for the last decade,
Buchanan draws a clear and nuanced picture of the costs
and benefits associated with using biomedical technology
to improve ourselves and our children.
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